Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC 50 value of 19.59 nM for insulin receptor . Insulin degludec can be used for the research of type 1 and type 2 diabetes
In Vitro
Insulin degludec (0.001-1000 nM; 12 h) binds with insulin receptor with an IC 50 value of 19.59 nM. Insulin degludec (200 nM; 10 min) increases glucose uptake in HL-1 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: HL-1 cardiomyocytes Concentration: 200 nM Incubation Time: 0-60 min Result: Decreased the level of Akt phosphorylation after 5 and 10 min treatment.
In Vivo
Insulin degludec (5 U/kg; s.c. once daily for 30 days) affects glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Swiss mice with diabetes Dosage: 5 U/kg Administration: Subcutaneous injection; 5 U/kg once daily for 30 days Result: Showed a fast response to insulin-induced hypoglycemia with a glycemic level at or slightly under 100 mg/dl after 60 min and this response effect can be abolished by cortisol. Diminished rates of glucose production and showed a low lactate production in livers. Increased the number of hepatocytes.
